Kronos Bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-11-11: Reporting owner Blunt Roshawn A.; Form 4; Security Director Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-10-04: Reporting owner Dinsmore Christopher; Form 4; Security Employee Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-09-07: Reporting owner Dinsmore Christopher; Form 4; Security Employee Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-08-02: Reporting owner Dinsmore Christopher; Form 4; Security Employee Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-11-11 | Blunt Roshawn A. Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,200 41,200 owned after | $17.10 exercise price | 2021-11-15 | |
| 2021-10-04 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,189 315,308 owned after | $3.27 exercise price | 2021-10-04 | |
| 2021-09-07 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,189 324,497 owned after | $3.27 exercise price | 2021-09-09 | |
| 2021-08-02 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,189 333,686 owned after | $3.27 exercise price | 2021-08-03 | |
| 2021-06-22 | Yang Taiyin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,150 5,150 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | De Backer Marianne Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,583 8,583 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | Ridloff Elena Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,450 15,450 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | Stampacchia Otello Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,600 20,600 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | Kazam Joshua A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,600 20,600 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | Belldegrun Arie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,600 20,600 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-06-22 | TANEN DAVID M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,600 20,600 owned after | $24.18 exercise price | 2021-06-23 | |
| 2021-03-25 | Yang Taiyin Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,200 41,200 owned after | $28.58 exercise price | 2021-03-26 | |
| 2021-01-25 | De Backer Marianne Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,200 41,200 owned after | $31.70 exercise price | 2021-01-27 |